How many investments has Foresite Capital made?

Foresite Capital has 212 tracked investments, 88 of which have exited, including 11 dated in the last 24 months.

What stage does Foresite Capital invest at?

Foresite Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

Where is Foresite Capital located?

Foresite Capital is headquartered in West Hollywood, US.

Does Foresite Capital lead rounds?

Foresite Capital has led 7 of the 31 rounds where its role is on record.

Who does Foresite Capital co-invest with?

Foresite Capital most often shares deals with RA Capital, OrbiMed, ARCH Venture Partners, among 247 tracked co-investors.

Foresite Capital

Venture capital

West Hollywood · Pre-Seed–Late Stage · 62 people tracked

Also known as FORESITE CAPITAL MANAGEMENT, LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Foresite Capital

3,102 people in our graph share verified history with the Foresite Capital team — schools, employers, funds. One of them is your warm intro.

Adam Valkinunlockedknows Hyung Chun · together at Harvard University (overlapped)

knows the team · via Kleiner Perkins

×2knows the team · via Coatue Management

×2knows the team · via BlackRock

knows the team · via Wedbush Securities

×2knows the team · via Harvard Business School

✨ Fox Verdict

Investment thesis

Foresite Capital concentrates on the forces transforming healthcare, investing in people, ideas and discoveries that combine technology and biotechnology to personalize care and speed innovation and product development. The firm practices full-lifecycle investing, partnering with companies from incubation through IPO and beyond to have impact regardless of timing. Its team of investment analysts, MD/PhDs and data scientists collaborates closely with portfolio companies, drawing on operational and investment experience and an extensive healthcare network. The firm believes healthcare is undergoing unprecedented innovation fueled by growing understanding of biologic and genetic information, and aims to use its capital and networks to build transformative companies improving the U.S. healthcare system.

Invests inAI & Machine Learning Biotech Digital Health Healthtech Longevity Medical Devices Larkspur United States West Hollywood

Source: firm website, verified Sep 15, 2026.

Stage

Pre-Seed–Late Stage

West Hollywood, CA, US

Instruments

Equity

Founded

2011

Last 12 months

7 investments

AUM

$3.2B

Tracked investments

212

Unicorns

IPOs

Acquisitions

Team · 62 people

from the firm's website & curated & public directories

Jim Tananbaum· Founder & CEO· San Francisco, Californiain 𝕏

Jim Tananbaum is founder and CEO of Foresite Capital Management, a healthcare-focused investment firm based in the San Francisco Bay Area with approximately $4 billion in assets under management as of December 2021. The firm invests in healthcare companies across multiple stages and employs clinical scientists, engineers, analysts, and partners to support portfolio companies.

Jim Tananbaum, MD· Founder & CEO

Dorothy Margolskee· MD· New Jerseyin

Dorothy Margolskee joined Foresite Capital in 2012, where she has overseen the firm's research and development evaluation group and built an early version of its investment technical review process for analyzing biotechnology portfolios. She previously served as Managing Director in charge of Research at Prospect Ventures, and earlier spent 15 years in drug development at Merck Research Labs, rising to Senior Vice President and contributing to programs including several vaccines and HIV treatments. She holds an M.D. from Johns Hopkins Medical School and a B.A. from Harvard University, and is board certified in Internal Medicine and Pulmonary.

Dorothy Margolskee, MD· Managing Director

Hadi Tabbaa· Managing Director· Darien, Connecticut, United Statesin

Hadi Tabbaa is a Managing Director at Foresite Capital, working in alternative asset management. His areas of focus include capital raising, investor relations, business development, sales, and mergers and acquisitions.

Hyung Chun· MD, Investment Team· New Haven, Connecticutin

Hyung Chun is a physician scientist who joined Foresite Capital in 2021, where he evaluates investment opportunities in private and public biotech companies. Before Foresite, he was a tenured faculty member at Yale School of Medicine, where he held roles including Co-Director of the Yale Cardiovascular Research Center, and remains an adjunct faculty member. He earned an A.B. in Biochemical Sciences from Harvard College and an M.D. from Johns Hopkins, and completed his residency and cardiovascular fellowship at Stanford.

Hyung Chun, MD· Partner

Michael Rome· Managing Director· Los Angeles, Californiain

Michael Rome, PhD· Managing Director

Richard Lau· Partner· New York, New Yorkin

Richard Lau joined Foresite Capital in 2014, where he works on the investment team handling due diligence and financial modeling of potential investments. He previously served as an equity research analyst covering specialty pharmaceuticals at Wedbush PacGrow Life Sciences and began his career at Pacific Growth Equities, rising from equity research associate to senior analyst covering biotechnology. He holds a B.A. in Molecular and Cell Biology with a biochemistry concentration from UC Berkeley and is a CFA Charterholder.

Richard Lau, CFA· Managing Director

Shannon Bergstedt· Partner· New York, New Yorkin 𝕏

Shannon Bergstedt is a member of the Investment Team at Foresite Capital, where she focuses on life sciences and healthcare technology. She previously spent six years at Verily (formerly Google Life Sciences) as a Business Development Lead, was on the founding team of Evidation Health, and held roles at GE Ventures, Kleiner Perkins, and CardioDx. She holds Bachelor's and Master's degrees from Stanford University and an MBA from Harvard Business School.

Stephen C. Peterson, CFA· Managing Director

Stephen C. Peterson has invested professionally in debt and equity securities since 2004. He is a CFA Charterholder and a member of the CFA Institute and the CFA Society of Colorado. He also serves as a guest lecturer on financial modeling and investment analysis at UC Berkeley's Haas School of Business, the University of Denver's Daniels College of Business, the University of San Francisco, and San Francisco State University.

Stephen Peterson· Partner· Denver, Coloradoin

Stephen Peterson is a Managing Director at Foresite Capital Management, where he identifies and evaluates investment opportunities in healthcare technology and services. He joined the firm in 2011 as its second investment team member and serves on its investment and valuation committees, along with holding board positions at Sollis Health and board observer roles at Thyme Care, Signant Health, and ConnectiveRx. Peterson previously worked as an equity analyst at Palo Alto Investors and Wells Fargo, holds the CFA Charter, and has lectured on investment analysis and financial modeling at multiple universities.

Dennis Ryan· Managing Director· Californiain

Collin Yang-Wong· Principal· San Francisco, Californiain

Deepak Atri, MD· Principal· United States

Vishal Deshmukh· Member of the Investment Team

Vishal Deshmukh is a member of the investment team at Foresite Capital, where he evaluates investment opportunities in biotech companies. He previously served as Director of Discovery Biology at Kinnate Biopharma, leading early discovery and development of small molecule oncology therapeutics, and as Director of Biology at Biosplice Therapeutics, where he managed programs across oncology, musculoskeletal, and dermatology areas. Earlier he was a Visiting Scientist at Calibr and the Genomics Institute of the Novartis Research Foundation, and he holds a Ph.D. in Biology from The Scripps Research Institute, an M.S. in Biotechnology from UC Irvine, and a B.S. in Pharmaceutical Sciences from the Institute of Chemical Technology, Mumbai.

Vishal Deshmukh, PhD· Principal

Edward Liang· Director· San Francisco, California, United Statesin

Justin Niu· Principal· Beijing, Chinain

Justin Niu is a partner at IDG Capital investing across big data, cloud computing and artificial intelligence, with a portfolio that includes enterprise-software company DEEPEXI.

Jorge Reis-Filho, MD, PhD, FRCPath· Venture Partner

Liang Chang, PhD· Venture Partner

Mike Lai, MD· Venture Partner

Travis Young, PhD· Venture Partner

Uplaksh Kumar· Venture Partner· San Francisco Bay Areain

Uplaksh Kumar is a venture partner at Foresite Capital. He previously served as SVP of strategic operations and scale at GRAIL, where he launched the Galleri multi-cancer early detection test, and was the first head of operations at Verily. He has held leadership roles at Life Technologies, BD, LONZA, and Qiagen, and co-founded RoosterBio, a regenerative medicine company focused on research and clinical-grade stem cells.

Alex M. Azar II· Advisor

Alex Azar served as the 24th Secretary of the U.S. Department of Health and Human Services from 2018 to 2021, overseeing a workforce of more than 85,000 and a budget exceeding $1.4 trillion. In that role he oversaw Operation Warp Speed to develop COVID-19 vaccines and therapeutics, and led initiatives on drug pricing, telehealth expansion, health record interoperability, the opioid crisis, and global health security. He has held senior roles in both U.S. government and the private sector, focused on healthcare.

Amelia Stoj· CCO and Assistant General Counsel· San Francisco, California, United Statesin

Cynthia Carpenter· Executive Associate· Esparto, California, United Statesin

Cynthia Carpenter supports the office of the CEO at Foresite Capital. She has over two decades of experience assisting C-level executives, including a prior role supporting Jim Tananbaum at Prospect Venture Partners and serving as an executive assistant to the co-founder at CKS Partners.

Darren Haggerty· Operations Investment Analyst· San Francisco Bay Areain

Darren Haggerty handles the review and reconciliation of the firm's private and public holdings and records associated trading activity. He is an operations and finance professional with more than 20 years of experience in private equity, and previously served as director of operations for Lighthouse Capital. He also has consulting experience.

Deepak Atri· Investment Team· United Statesin 𝕏

Deepak Atri joined Foresite Capital in 2022 as part of the investment team, where he evaluates opportunities in biotech and healthcare companies. A physician-scientist, he earned his MD at Yale as a Howard Hughes Medical Institute research fellow, and completed clinical training in medicine at The Johns Hopkins Hospital and cardiovascular medicine at Brigham & Women's Hospital. He also did a postdoctoral fellowship in molecular and population genetics with Brigham & Women's and The Broad Institute of MIT & Harvard.

Insiya Essani· Senior Associate· Burlingame, California, United Statesin

Insiya Essani is a member of the investment team at Foresite Capital, where she focuses on therapeutics investment opportunities. She previously worked as a Life Science Consultant at ClearView Healthcare Partners on strategic and due diligence projects for pharma, biotech, and life sciences clients, and held earlier roles at Barclays and Bristol Myers Squibb. She holds a B.A. in Chemistry from Princeton University.

Jacqueline Guttman· Director, IR & Capital Formation· San Francisco Bay Areain

Jacqueline Guttman joined Foresite Capital in 2021 as an Associate Director on the Investor Relations team, where she supports the firm's existing limited partners and manages communications, external events, and content development. She previously spent nearly five years on the investments team at the Carnegie Corporation of New York and worked as an analyst at TD Securities. She holds a Bachelor of Arts in Economics from Barnard College, Columbia University.

Jody Dutton· Senior Executive Administrator· San Francisco, California, United Statesin

Jody Dutton joined Foresite Capital in 2012 as an early member of the administrative team and provides executive support to the investment team. Before joining the firm, she worked for 10 years as an executive assistant to the President of Food & Beverage at a casino in Northern California, where she handled travel, meetings, and menu planning and design and assisted with two expansions.

Jorge Campos· Compliance Manager

Jorge Campos is a member of Foresite Capital's compliance team, where he helps develop, implement, and maintain the firm's compliance program. He has around eight years of experience in compliance, previously serving as Senior Compliance Associate at CVC Credit Partners and earlier working at the compliance consultancy Cordium.

Kaitlin Montgomery· Executive Assistant

Kara Govi· Executive Assistant

Kara Govi supports the office of the CEO at Foresite Capital. Her background includes senior executive assistant roles across venture capital, startups, and executive search. She holds a degree in Advertising with a minor in Personality and Social Psychology from San Diego State University.

Kelly Ashauer· Executive Assistantin

Kelly Ashauer joined Foresite Capital in 2018, where she provides executive support to the investment team and Investor Relations leadership. Before Foresite, she held roles in the Education and Training office of the Department of Medicine at Memorial Sloan Kettering Cancer Center, most recently supporting the Transitional Year Residency Program. She holds a B.A. in Business Communications from Rockhurst University in Kansas City, MO.

Kevin Kelly· Head of Strategic Trading & ECM Relations· Burlingame, California, United Statesin

Kevin Kelly joined Foresite Capital in 2018 as a member of the investment team, working on trading that is cost effective and compliant. He has over 20 years of experience in institutional asset management with a focus on SMID Cap trading, operations, and investment process optimization, having previously served as head trader and vice president of operations at RS Investments and beginning his career at Putnam Investments in international trade support. He holds a B.A. from Connecticut College with a concentration in political economies.

Lisa Klyse· Operations Office Manager· New York, New York, United Statesin

Lisa Klyse is an administrative professional with more than 20 years of experience supporting executives across various industries. She joined Foresite Capital in 2019 to support the operations team and the Chief Financial Officer, having previously worked in institutional equity sales supporting sales and trading executives. She holds a B.S. in Hospitality Management from the University of Nevada, Las Vegas.

Lisa Lau· Sr. Manager, Finance & Accounting· San Francisco Bay Areain

Lisa Lau joined Foresite Capital in 2018, where she supports the firm's accounting and operational functions. She previously served as assistant controller at Industrial Growth Partners, a private equity firm, and earlier worked as a tax accountant focused on alternative investments and partnership and corporate entities across the hedge fund, technology, and real estate industries. She holds a BS in Managerial Economics from the University of California, Davis and an MS in Taxation from Golden Gate University.

Liz Canis· Executive Advisor

Liz Canis is an executive advisor at Foresite Capital Management, where she sources opportunities, oversees diligence, monitors portfolio assets, and supports internal incubation efforts. She previously served as vice president of emerging business and partnerships at Elevance Health, ventures lead at healthcare venture firm Savvysherpa, and founder and CEO of The Pivot Group. Earlier she spent eleven years in leadership roles at UnitedHealth Group. She holds a BA from Northwestern University and an MBA from the University of Michigan Ross School of Business.

Luke Bagaason· Manager of Portfolio Valuation· Denver, Coloradoin

Luke Bagaason joined Foresite Capital in 2014 as an analyst and currently serves as Manager of Portfolio Valuation, overseeing monitoring of the firm's privately held investment portfolio. Before Foresite, he operated his own registered investment advisory providing asset management and consulting to investment firms and individuals, and previously worked at JP Morgan Asset Management starting in 2007. He earned the CFA designation in 2013.

Luke Bagaason, CFA· Director, Portfolio Valuation· Denver, Colorado, United Statesin

Madiha Raziuddin· Director, Human Resources

Mark Ponticelli· Executive Advisor

Mark Ponticelli, CFA· Executive Advisor

Mathai Mammen· Advisor

Mathai Mammen has advised Foresite Capital since 2019 and is Chairman and CEO of Parabilis Medicines (formerly FogPharma). He previously served on the Executive Committee of Johnson & Johnson as EVP of J&J Pharmaceuticals R&D and was senior vice president at Merck Research Laboratories, leading research across cardiovascular, metabolic, renal, oncology/immuno-oncology and immunology areas. Earlier he co-founded and led R&D at Theravance, which he built on science from his PhD at Harvard University, and spun out Innoviva and Theravance Biopharma.

Max Lien· Director, IR & Capital Formation

Max Lien joined Foresite Capital in 2023, where he handles investor relations and business development. He previously served as VP of Business & Corporate Development at Hyperscience, an enterprise AI company, where he built the team globally and established partnerships with firms including McKinsey, IBM, and AWS. Earlier in his career, he worked on strategy and corporate/business development teams at Bloomberg and BlackRock, focusing on M&A, partnerships, and growth across financial services, software, and AI.

Melia Granath Panelo· Associate

Nicole McCann· Administrative Assistant· Darien, Connecticut, United Statesin

Nicole McCann joined Foresite Capital in 2011, where she supports the administrative team with functions ranging from data entry to process development. She previously held business office roles at Ford on the operations team, working with accounting, human resources, and payroll. She holds an AA with an Accounting concentration from Liberty University and is pursuing a B.S. in Accounting and Business Administration.

Robert Gunderson· Advisor

Robert (Bob) Gunderson is the founding partner and now Chairman Emeritus of Gunderson Dettmer, an international law firm serving emerging growth companies and venture capital and growth equity investors. Over four decades he advised parties in venture financings, IPOs, M&A and fund formations. He co-edited a text on venture capital and public offering negotiation, is a fellow of the American College of Governance Counsel and the American Bar Foundation, and has served as a director of several public companies.

Rowena Dayanghirang· Paralegal· San Francisco Bay Areain

Rowena Dayanghirang supports fund transactions and legal matters at Foresite Capital. Before joining the firm, she spent over five years as a Corporate Paralegal at Gunderson Dettmer, LLP, handling corporate and transactional work for private companies across various industries. She previously worked as a Corporate Paralegal Assistant at Perkins Coie, LLP for two years.

Susan Gatrill· Manager, Fund Accounting· San Francisco, California, United Statesin

Susan Gatrill joined Foresite Capital's accounting team in 2015, where she handles review, reconciliation, and analysis of fund financial activity along with quarterly reporting. She has close to 20 years of experience in venture capital accounting, including 13 years as a fund accountant and later senior accountant at Lighthouse Capital Partners, a venture debt firm, where she managed daily operations and monthly and quarterly close for multiple investment funds.

The Honorable Alex M. Azar II· Advisor

Tiffany Bond· Sr. Accounting & Administration Associate

Tiffany Bond handles day-to-day accounting for Foresite Capital's entities, including accounts payable and receivable, capital call and cash distribution processing, and daily cash management. She joined the firm in November 2014. Before that, she was the office and technology manager at Kreuzberger|Associates, a finance and accounting recruiting firm in the San Francisco Bay Area.

Vikram Bajaj, PhD· Advisor

Charmaine Villasin· Administrative Assistant· Metro Cebuin

Charmaine Villasin is a Talent Researcher at EVP, where she began by supporting portfolio companies with recruitment and HR. She later expanded into the firm's investment activities focused on early-stage software companies in Australia and New Zealand, and as Head of Origination she identifies, engages with, and invests in high-growth businesses.

Jacob Barlow· Senior Associate, Life Sciences Research· Worcester, Massachusettsin

Jenny Chen· Office Operations Manager· Greater Sydney Areain

Khobi Deep· Analyst· Sydney, New South Wales, Australiain

Marguerite Davis· Delaware

Founder mafia

3 people who came through Foresite Capital went on to found or lead other companies.

Jacob RobinsonVenture FellowFounded VO Health +1 Stella SarrafSenior Research AnalystFounded Spinogenix +1 Damien SoghoianDirectorFounded Seranova Bio

What they invest in

from 162 of 212 portfolio companies

Biotech ×134Healthtech ×99Medical Devices ×59Digital Health ×30AI & Machine Learning ×22Deep Tech ×17Enterprise Software ×5Hardware ×5

HQs:United States×118United Kingdom×4Denmark×1Netherlands×1

Who they back

founder profiles across 76 portfolio companies

49%

solo founders

37 of 76 mapped founding teams

48%

repeat founders

of 67 founders with career history

~2 yrs

old at investment

median across 34 dated deals

Founding team size:solo founder×372 founders×293 founders×64+ founders×4

Where their founders studiedfrom 66 founders with education data

Harvard University ×6Massachusetts Institute of Technology ×4Stanford University ×4University of California, Berkeley ×4Brown University ×3University of Pennsylvania ×3Duke University ×2Heidelberg University ×2

What their founders studiedfrom 64 founders with field-of-study data

Life Sciences ×26Chemistry ×12Engineering ×10Business & Management ×7Computer Science ×6Medicine ×6Physics ×5Economics ×4

Where their founders worked beforefrom 67 founders with career history

Stanford University ×7Harvard Medical School ×3Amgen ×2AstraZeneca ×2Atlas Venture ×2Exelixis ×2Flatiron Health ×2GlaxoSmithKline ×2

43 founders hold a PhD · 10 hold an MBA (of 66 with degree data)

Investments · 212 tracked

founders shown can be your intro path

By year:2026 · 5 2025 · 5 2024 · 10 2022 · 5 2021 · 8 2020 · 5 2019 · 3 2018 · 5 2017 · 3 2016 · 5 2015 · 8 2014 · 568 dated

Alumisalumis.com in 𝕏NASDAQ: ALMSJul 2024

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)in Jack Danilkowicz(Chief Commercial Officer)in Jörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in

Board seatJames Tananbaum· per SEC Form D

Co-investorsNextech Invest OrbiMed Samsara BioCapital SR One Capital Management venBio Partners Westlake Village BioPartners +1 more

Fulcrum Therapeutics inNASDAQ: FULCAug 2018

Fulcrum Therapeutics develops small-molecule drugs targeting rare genetic diseases with significant unmet treatment needs, with its lead candidate pociredir in clinical testing for sickle cell disease as an oral therapy designed to increase fetal hemoglobin levels.

BiotechCambridge, US

Robert Gould(Executive Officer, Director)in Alex C. Sapir(President and Chief Executive Officer, Director)in

Board Alan Ezekowitz(Director)in Mark Levin(Director)inJames Geraghty(Director)James Collins(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsThird Rock Ventures

10x Genomics 1-color10xgenomics.com in 𝕏NASDAQ: TXGMay 2019

10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers.

BiotechDeep TechHardwareHealthtechPleasanton, US

Serge Saxonov(Founder)inBen Hindson(Founder)inBrad Crutchfield(Chief Commercial Officer)Jean Philibert(Chief People Officer)Eric S Whitaker(General Counsel)inJustin McAnear(Chief Financial Officer)

Co-investorsFoothill Ventures Khosla Ventures OMX Ventures Paladin Capital Group SoftBank Vision Fund Venrock +4 more

Aclaris Therapeuticsaclaristx.comNASDAQ: ACRS

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)inJoseph Monahan(Executive Officer)in Hugh Davis(Executive Officer, Director)inJames Loerop(Executive Officer)

Co-investorsAisling Capital APERTURE Venture Partners F-Prime Capital RA Capital Sofinnova Ventures Sofinnova Venture Partners +1 more

Adagio TherapeuticsNASDAQ: IVVDApr 2021 · $336M

Invivyd develops monoclonal antibody therapies to prevent and treat serious viral infections, beginning with COVID-19 and expanding to respiratory syncytial virus and measles.

BiotechWaltham, US

Tillman U. Gerngross(Executive Officer, Director)Lynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)inEllie Hershberger(Executive Officer)

Co-investorsFidelity Investments GV (Google Ventures)MITHRIL Mithril Capital Management OrbiMed Polaris Partners +3 more

Adaptimmuneadaptimmune.com in 𝕏OTC: ADAPYSep 2014

Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.

BiotechHealthtechMedical DevicesAbingdon, Oxfordshire, US

James Noble(Chief Executive Officer)Adrian Rawcliffe(Chief Executive Officer and Director)in Gavin Wood(Chief Financial Officer)in William Bertrand(Chief Operating Officer)in John Lunger(Chief Patient Supply Officer)inElliot Norry(Chief Medical Officer)in

Co-investorsAvoro Capital Advisors Eight Roads Ventures F-Prime Capital New Enterprise Associates (NEA)Ridgeback Capital

Adaptive Biotechnologiesadaptivebiotech.com in 𝕏NASDAQ: ADPT

Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US

Chad Robins(Executive Officer, Director)in Harlan Robins(Executive Officer)in Kathleen Determann(Executive Officer)inDean Schorno(Executive Officer)inChris Carlson(Executive Officer)Kyle Piskel(Chief Financial Officer)in

Co-investorsDecheng Capital FMG Capital Khosla Ventures OrbiMed

Adicet Bioadicetbio.comNASDAQ: ACET

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in

Board Jonathan Silverstein(Director)in Carl Gordon(Director)inFlorent Gros(Director)

Co-investorsOrbiMed Pontifax Venture Capital Quan Capital aMoon Novartis Venture Fund PureTech Health

Alectoralector.com in 𝕏NASDAQ: ALECSep 2015

Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US

Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in

BoardCarl Gordon(Director)Terry McGuire(Director)in

Co-investorsMission Bay Capital Mission Biocapital MRL Ventures Fund SV Health Investors Polaris Partners

Allogene Therapeuticsallogene.com in 𝕏NASDAQ: ALLOApr 2018

Allogene Therapeutics develops allogeneic CAR T cell therapies (AlloCAR T) for blood cancers, solid tumors, and autoimmune diseases, using off-the-shelf manufactured cell products rather than patient-derived autologous approaches.

BiotechHealthtechMedical DevicesSouth San Francisco, US

ROBERT ABRAHAM(Director)JOSHUA A. KAZAM(Executive Officer, Director)DAVID M. TANEN(Executive Officer)FRANZ HUMER(Director)JOHN DEYOUNG(Director)

Board OWEN WITTE(Director)

Co-investorsAvoro Capital Advisors TPG Vida Ventures Gilead Sciences VVAG Special

Alx Oncologyalxoncology.com in 𝕏NASDAQ: ALXO

ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.

BiotechHealthtechMedical Devices

Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in

Co-investorsLightstone Ventures age1 venBio Partners Logos Vivo Capital

Arbutus Biopharma Corporationarbutusbio.com inNASDAQ: ABUSDec 2016

Arbutus is a biotechnology company developing therapeutic assets and bringing them to market, with expertise spanning scientific, clinical, operational, and financial development.

BiotechHealthtechWarminster, US

William H. Collier(President and Chief Executive Officer)inGaston Picchio(Chief Development Officer)inMichael J. McElhaugh(Chief Business Officer)in David C. Hastings(Chief Financial Officer)in Michael J. Sofia(Chief Scientific Officer)inElizabeth Howard(Executive Officer)in

Aura Biosciencesaurabiosciences.com in 𝕏NASDAQ: AURA

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsAdvent Life Sciences Chiesi Ventures Droia Ventures Jazzya Investments Medicxi Myelin VC +4 more

Beam Therapeuticsbeamtx.com in 𝕏NASDAQ: BEAMNov 2018

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

David R. Liu(Founder and Inventor)inJ. Keith Joung(Founder and Inventor)inFeng Zhang(Founder and Inventor)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)

Co-investorsARCH Venture Partners Dreamers VC Eight Roads Ventures F-Prime Capital GV (Google Ventures)HongShan Capital Group +1 more

Bicara Therapeuticsbicara.com in 𝕏NASDAQ: BCAX

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.

Ivan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)in David Raben(Chief Medical Officer)in

Co-investorsAisling Capital Eight Roads Ventures F-Prime Capital Premji Invest RA Capital Red Tree Venture +5 more

Casi Pharmaceuticalscasipharmaceuticals.com inOTC: CASIF

CASI Pharmaceuticals is a biopharmaceutical company developing CID-103, an investigational anti-CD38 monoclonal antibody targeting B memory, plasmablasts, and plasma cells.

BiotechHealthtechBeijing

Chunhua Wang(Chief Operating Officer)Wei Gao(General Counsel)Hai Huang(Global Chief Commercial Officer)Alexander A. Zukiwski(Chief Medical Officer)Wei (Larry) Zhang(President)Wei-Wu He(Chief Executive Officer, Chairman of the Board of Directors)

Celldex Therapeutics, Inc.celldex.com in 𝕏NASDAQ: CLDXNov 2016

Celldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation.

BiotechHealthtechHampton, US

Anthony S. Marucci(Executive Officer, Director)inAvery W. Catlin(Executive Officer)

BoardRichard van den Broek(Director)Timothy M. Shannon, M. D.(Director)Herbert J. Conrad(Director)Karen Shoos(Director)

CG Oncologycgoncology.com in 𝕏NASDAQ: CGON

CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.

BiotechHealthtechMedical Devices

Arthur Kuan(Chairman and Chief Executive Officer)in

Co-investorsDecheng Capital Longitude Capital Palm Drive Capital RA Capital TCG Crossover ACORN BIOVENTURES +2 more

Compass Therapeuticscompasstherapeutics.com in 𝕏NASDAQ: CMPXDec 2017

Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.

BiotechHealthtechCambridge, US

Schuetz Thomas(Executive Officer, Director)in Errik Anderson(Executive Officer, Director)in Thomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)in Neil Lerner(Senior Vice President, Chief Accounting Officer)in

Co-investorsBioBrit F-Prime Capital OrbiMed venBio Partners Vivo Capital Borealis Ventures +1 more

Crineticscrinetics.com in 𝕏NASDAQ: CRNX

Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.

BiotechSan Diego, US

Richard Scott Struthers(Executive Officer, Director)Stephen F. Betz(Executive Officer)in Stephen Betz(Chief Scientific Officer)in R. Scott Struthers(President, Chief Executive Officer and Director)in Tobin Schilke(Chief Financial Officer)in Isabel Kalofonos(Chief Commercial Officer)in

Co-investors5AM Ventures OrbiMed RA Capital Vivo Capital

Cullinan Therapeuticscullinantherapeutics.com in 𝕏NASDAQ: CGEM

Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.

BiotechHealthtechMedical Devices

Mary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)Jennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)in Nadim Ahmed(President and Chief Executive Officer)in

Co-investorsNextech Invest Biotechnology Value Fund OrbiMed

Cytokineticscytokinetics.com in 𝕏NASDAQ: CYTK

Cytokinetics develops potential medicines for cardiovascular and neuromuscular diseases characterized by impaired muscle function.

BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US

James SpudichinRonald ValeLawrence S.B. GoldsteinRobert I. Blum(President and Chief Executive Officer)in

BoardJames Sabry

Denali Therapeuticsdenalitherapeutics.com inNASDAQ: DNLIFeb 2024

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

Marc Tessier-Lavigne(Director)inRyan Watts(Executive Officer, Director)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)in

Co-investorsARCH Venture Partners EcoR1 Capital F-Prime Capital ARCH Venture Flagship Pioneering Flagship Ventures +1 more

Disc Medicinediscmedicine.com in 𝕏NASDAQ: IRON

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)in Jean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)in Pamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in

Co-investorsAccess Biotechnology Atlas Venture Bain Capital Life Sciences Frazier Life Sciences OrbiMed 5AM Ventures +6 more

Edgewise Therapeuticsedgewisetx.com in 𝕏NASDAQ: EWTX

Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.

BiotechDigital HealthBoulder, US

Kevin Koch(Executive Officer, Director)in Alan Russell(Director)in Badreddin Edris(Director and Co-Founder)inKenneth Harrison(Director)

Board Peter Thompson(Director)in Jonathan Root(Director)in

Co-investorsBoulder Ventures OrbiMed US Venture Partners Deerfield Management Company Novo Holdings

GH Researchghres.comNASDAQ: GHRS

A pharmaceutical company whose executive team emphasizes innovation and patient care.

BiotechDigital HealthMental Health

Co-investorsRA Capital

GRAILgrail.com in 𝕏NASDAQ: GRAL

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)Joshua Ofman, MD, MSHS(Chief Executive Officer)in Aaron Freidin(Executive Officer)in Josh Ofman(Executive Officer)inRobert Ragusa(Executive Officer, Director)Jennifer Cook(Executive Officer, Director)in

Co-investorsAmino Capital ARCH Venture Partners Bezos Expeditions Bluebird Ventures Decheng Capital Dentsu Ventures +8 more

Hinge Healthhingehealth.com in 𝕏NYSE: HNGE

Hinge Health builds a digital healthcare platform designed to help individuals manage musculoskeletal health and related conditions.

Digital HealthHealthtechMedical DevicesWellness & FitnessSan Francisco, US

Gabriel Mecklenburg(Executive Officer, Director)inDaniel Perez(Executive Officer, Director)in

Co-investors11.2 Capital Alkeon Innovation Bessemer Venture Partners Cannage Capital Coatue Management Duke Capital Partners +11 more

Insmedinsmed.com in 𝕏NASDAQ: INSM

Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.

BiotechDigital HealthHealthtechMedical Devices

Will Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSara Bonstein(Chief Financial Officer)inRoger Adsett(Chief Operating Officer)Martina Flammer(Chief Medical Officer)in S. Nicole Schaeffer(Chief People Strategy Officer)in

Co-investorsBessemer Venture Partners F-Prime Capital OrbiMed Prospect Venture Partners NVIDIA

Intellia Therapeuticsintelliatx.com in 𝕏NASDAQ: NTLAAug 2015

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Executive Officer, Director)inJennifer Doudna(Co-founder)Jose Rivera(Executive Officer)in John Leonard(President and Chief Executive Officer)in James Basta(Executive Vice President, General Counsel and Corporate Secretary)in Edward Dulac(Executive Vice President, Chief Financial Officer)in

Co-investorsage1 Atlas Venture Avoro Capital Advisors EcoR1 Capital Fidelity Investments OrbiMed

Invivydinvivyd.com in 𝕏NASDAQ: IVVD

Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications.

BiotechHealthtech

Marc Elia(Founder)in

Co-investorsBain Capital Life Sciences MRL Ventures Fund Premji Invest GV (Google Ventures)MITHRIL Mithril Capital Management +3 more

Kerostxkerostx.com inNASDAQ: KROS

Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart.

BiotechHealthtechLexington, US

Jasbir S. Seehra(Executive Officer, Director)inJasbir Seehra(Co-Founder, Chief Executive Officer and Director)in

BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)in

Co-investorsArkin Capital OrbiMed Pontifax Venture Capital

Kura Oncologykuraoncology.com inNASDAQ: KURA

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

TROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYI LIU(Executive Officer)in Troy Wilson(Founder)in Troy E. Wilson(President and Chief Executive Officer, Chairman of the Board)inHEIDI HENSON(Executive Officer)in

Co-investorsARCH Venture Partners Avoro Capital Advisors EcoR1 Capital Nextech Invest OUP (Osage University Partners)ARCH Venture

Madrigalmadrigalpharma.com in 𝕏NASDAQ: MDGLApr 2016

Madrigal Pharmaceuticals is a biopharmaceutical company developing treatments for metabolic-associated steatohepatitis (MASH).

BiotechHealthtechMedical DevicesConshohocken, US

Rebecca Taub(Founder and Director)in Marc R. Schneebaum(Executive Officer)inPaul A. Friedman(Executive Officer, Director)in Bill Sibold(President and Chief Executive Officer)inMardi Dier(Executive Vice President and Chief Financial Officer)in Carole Huntsman(Executive Vice President and Chief Commercial Officer)in

Co-investorsAvoro Capital Advisors Bay City Capital

Maze Therapeuticsmazetx.com in 𝕏NASDAQ: MAZE

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in

Co-investorsAndreessen Horowitz ARCH Venture Partners Frazier Life Sciences GV (Google Ventures)Frazier Healthcare Partners Janus Henderson Investors +3 more

Nateranatera.com in 𝕏NASDAQ: NTRA

Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.

BiotechDigital HealthHealthtechMedical Devices

Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)

Co-investorsBain Capital Life Sciences Cheyenne Ventures Claremont Creek Ventures Harmony Partners Lightspeed Venture Partners RA Capital +2 more

Olemaolema.com in 𝕏NASDAQ: OLMA

Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.

BiotechHealthtechSan Francisco, US

Cyrus L. Harmon, Ph.D.(Director)Cyrus Harmon(Executive Officer, Director)in Cyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)in

Co-investorsAvoro Capital Advisors Bain Capital Life Sciences Lightspeed Venture Partners RA Capital Biotechnology Value Fund Logos +1 more

Omeros Corp.omeros.comNASDAQ: OMER

Omeros is a publicly traded biotech company developing a diverse pipeline of first-in-class small-molecule and antibody therapeutics targeting unmet medical needs across multiple therapeutic areas and indications.

BiotechHealthtechMedical DevicesSeattle, US

Co-investorsSPRINGROCK VENTURES

Parabilis Medicinesparabilismed.com inNASDAQ: PBLS

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

Mathai Mammen(CEO, President and Chairman)in

Co-investorsARCH Venture Partners Catalio Capital Management, LP Frazier Life Sciences General Catalyst Nextech Invest RA Capital +7 more

Quince TherapeuticsNASDAQ: QNCX

Quince Therapeutics is a biotechnology company developing the AIDE technology platform, a drug/device combination that encapsulates medications into a patient's own red blood cells to improve drug delivery for rare diseases.

BiotechSouth San Francisco, US

Stephen Dominy(Director)Casey Lynch(Executive Officer, Director)Charles Ryan(Executive Officer)inBrendan Hannah(Executive Officer)Dirk Thye(Executive Officer, Director)inKristen Gafric(Executive Officer)

Co-investorsSofinnova Partners Takeda Ventures

Relayrelaytx.com in 𝕏NASDAQ: RLAYJan 2024

Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.

AI & Machine LearningBiotechDeep TechCambridge, US

Donald A. Bergstrom(Executive Officer)in Sanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)

Co-investorsCommonweal Ventures EcoR1 Capital Nextech Invest SoftBank Vision Fund Curie.Bio General Catalyst +1 more

Replimunereplimune.com in 𝕏NASDAQ: REPL

Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.

BiotechHealthtechMedical Devices

Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)

Co-investorsAtlas Venture Bain Capital Life Sciences REDMILE

Revolution MedicinesNASDAQ: RVMD

Revolution Medicines develops drug candidates targeting specific genetic mutations in cancer and other serious diseases, advancing them through clinical trials toward regulatory approval and commercialization.

BiotechRedwood City, US

Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)

Co-investorsBain Capital Life Sciences Nextech Invest The Column Group Third Rock Ventures

Rxsightrxsight.com in 𝕏NASDAQ: RXST

RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.

HealthtechMedical DevicesPasadena, US

Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRon Kurtz(President, Chief Executive Officer & Director)Mark Wilterding(Chief Financial Officer)in

Co-investorsFlying L Partners H.I.G. Capital H.I.G. HealthBridge Partners Longitude Capital RA Capital Visionary Ventures +2 more

Scynexisscynexis.com in 𝕏NASDAQ: SCYX

SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections.

BiotechDurham, US

Yves J. Ribeill(Executive Officer, Director)inCharles F. Osborne, Jr.(Executive Officer)Brian Schwab(Executive Officer)in David Angulo(Chief Executive Officer, President and Director)in

BoardLaurent Arthaud(Director)Mounia Chaoui(Director)

Co-investorsDecheng Capital Deerfield Management Company RA Capital

Seaport Therapeuticsseaporttx.com in 𝕏NASDAQ: SPTXOct 2024

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

Daphne Zohar(Founder, CEO and Board Member)in Michael Chen(Executive Officer)in Lana Gladstein(Executive Officer)in Antony Loebel(Executive Officer)in Eric Green(Executive Officer)in

Board James I. Healy(Director)

Co-investorsARCH Venture Partners HAWKTAIL PureTech Health Sofinnova Ventures Third Rock Ventures

Silence Therapeuticssilence-therapeutics.comNASDAQ: SLNFeb 2021

Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.

BiotechLondon

Craig Tooman(Executive Officer)inGiles Campion(Executive Officer)Mark Rothera(Executive Officer, Director)inBarbara Ruskin(Executive Officer)

BoardJames Ede-Golightly(Director)Alistair Gray(Director)

Co-investorsMC Healthcare Ventures Nextech Invest Vivo Capital

Solid Biosciencessolidbio.com in 𝕏NASDAQ: SLDB

Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.

BiotechHealthtechCharlestown, US

Ilan Ganot(Co-Founder and Director)inStephen DiPalma(Executive Officer)Carl Morris(Executive Officer)inAlexander Cumbo(President, Chief Executive Officer and Director)Martin Freed(Director)inPaul Herizch(Executive Officer)

Co-investorsBain Capital Life Sciences RA Capital

SutroVaxNASDAQ: PCVX

BiotechSouth San Francisco, US

Grant E. Pickering(Chief Executive Officer)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in

Co-investorsAbingworth CTI Life Sciences Fund L.P.Frazier Life Sciences Janus Henderson Investors Longitude Capital Medicxi +4 more

Syndax Pharmaceuticals inNASDAQ: SNDX

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)in Arlene Morris(Executive Officer, Director)in Michael A. Metzger(Chief Executive Officer)in Keith A. Goldan(Chief Financial Officer)in

Board Dennis Podlesak(Director)inIvor Royston(Director)

Co-investorsPappas Capital Sofinnova Ventures venBio Partners BlackRock Domain Associates MPM BioImpact

Tango Therapeuticstangotx.comNASDAQ: TNGX

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.

BiotechBoston, US

Alan Huang(Executive Officer)in Adam Crystal(Executive Officer)inDaniella Beckman(Executive Officer)inDouglas Barry(Executive Officer)Aaron Davis(Director)

Board Barbara Weber(Executive Officer, Director)in

Co-investorsNextech Invest NSG Ventures Third Rock Ventures

Vaxcytevaxcyte.comNASDAQ: PCVX

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

Grant Pickering(Founder)in Grant E. Pickering(Chief Executive Officer and Director)in

Co-investorsBioRock Ventures CTI Life Sciences Fund L.P.Frazier Life Sciences Longitude Capital RA Capital Janus Henderson Investors +2 more

Verastemverastem.com in 𝕏NASDAQ: VSTM

Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.

BiotechMedical DevicesNeedham, US

Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)in CATHY CAREW(Executive Officer)in JONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in

Co-investorsBessemer Venture Partners Cardinal Partners Lightstone Ventures Longwood Fund Oberland Capital OrbiMed

Wave Life Scienceswavelifesciences.com in 𝕏NASDAQ: WVE

Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity.

BiotechHealthtechLongevitySingapore

Takeshi Wada(Director)inGregory L. Verdine(Director)Paul B. Bolno, M.D.(Executive Officer, Director)in

Board Peter Kolchinsky(Director)inKen Takanashi(Director)Masaharu Tanaka(Director)

Co-investorsRA Capital

Xenon Pharmaxenon-pharma.com in 𝕏NASDAQ: XENE

Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders.

BiotechHealthtech

Ian Mortimer(President and Chief Executive Officer)in Darren Cline(Chief Commercial Officer)in Andrea DiFabio(Chief Legal Officer and Corporate Secretary)in James Empfield(Executive Vice President, Drug Discovery)inTucker Kelly(Chief Financial Officer)in Chris Kenney(Chief Medical Officer)in

Co-investorsArcher Capital Group Archer Venture Capital Avoro Capital Advisors New Enterprise Associates (NEA)

Remix Therapeuticsremixtx.com in 𝕏Jan 2024 · $70M✓ verified

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRobert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)in Matthew Patterson(Director)in Scott Biller(Director)in

Board seat Michael Rome· per SEC Form D

Co-investorsAtlas Venture The Column Group ARCH Venture Partners Decheng Capital

Bit Biobit.bio in 𝕏Jun 2020 · $41.5M✓ verified

bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.

BiotechDeep TechHealthtechMedical Devices

Dr Mark Kotter(Founder)Przemek Obloj(CEO)in Emma Pepperell in

Co-investorsBlueYard Capital ARCH Venture Partners Dynamk Capital Good AI Capital HAWKTAIL Metaplanet +2 more

Cerevancecerevance.com in 𝕏✓ verified

Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US

Craig Thompson(Chief Executive Officer)in Sagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)in Ottavio V. Vitolo(Chief Medical Officer)in

Co-investorsGV (Google Ventures)Dementia Discovery Fund SV Life Sciences Dementia Discovery Lightstone Ventures SV Health Investors +3 more

Curisiumhealthverity.com in 𝕏✓ verified

HealthVerity operates a healthcare and consumer data ecosystem that enables HIPAA-compliant synchronization and exchange of real-world data across pharma, payers, and government agencies.

Data & InfrastructureEnterprise SoftwareHealthtechPhiladelphia, US

Andrew Kress(Co-Founder and CEO)inAndrew Goldberg(Co-Founder and COO)

Board Michael Greeley(Director)inRachel Winokur(Director)

Co-investorsFlare Capital Partners Greycroft New Enterprise Associates (NEA)

Engrail Therapeuticsengrail.com in✓ verified

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsLongwood Fund Norwest Venture Partners RiverVest Venture Partners Ysios Capital abrdn plc Eight Roads Ventures +4 more

Pleno Inc.plenoinc.com in✓ verified

Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.

BiotechHardwareHealthtech

Co-investorsMedical Excellence Capital Deerfield Management Company

Spearspear.bio in 𝕏✓ verified

Spear Bio develops high-sensitivity immunoassays based on its SPEAR (Successive Proximity Extension Amplification Reaction) technology, which originated from research at the Wyss Institute.

BiotechHealthtechMedical Devices

Feng Xuan(Chief Executive Officer & Co-founder)Peng Yin(Director & Co-Founder)

Co-investorsMaverick Ventures Yonghua Capital

Kinnate Biopharmakinnate.comDec 2019

BiotechSan Diego, US

Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)

BoardBret Zbar(Director)Carl Gordon(Director)

Board seat Michael Rome· per SEC Form D

Co-investorsNextech Invest Janus Henderson Investors RA Capital Venrock Healthcare Capital Partners Viking Global Investors

Pardes Biosciencespardesbio.com inFeb 2021

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

BiotechHealthtechSan Francisco, US

Uri Lopatin(Founder/CEO)inUri A. Loptain(Executive Officer, Director)Heidi Henson(Executive Officer)inElizabeth Lacy(Executive Officer)Lee Arnold(Executive Officer)

BoardJ. Jay Lobell(Director)

Board seatJames B. Tananbaum· per SEC Form D

Co-investorsY Combinator Khosla Ventures

Riskgamingriskgaming.com inFeb 2025

Riskgaming creates immersive strategy simulation games where high-level decision-makers assume roles and navigate complex scenarios involving technology, business, and geopolitical challenges to explore alternative outcomes and inform real-world decisions.

BiotechHayward, US

Kegan Schouwenburg(Executive Officer, Director)Roger M. Perlmutter(Executive Officer, Director)in

Board Joshua Wolfe(Director)inDror Berman(Director)Leon Chen(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsBain Capital Life Sciences Cisco Investments Lux Capital Dimension Capital

Tarsa Therapeuticstarsatherapeutics.comFeb 2016

Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.

BiotechPhiladelphia, US

David Brand(Executive Officer, Director)inGregory Lumpkin(Executive Officer)

BoardRichard Kollender(Director)Martin Edwards(Director)Eric Bednarski(Director)Derek Ferguson(Director)

Board seatJames Tananbaum· per SEC Form D

Co-investorsMVM Life Science Partners Oxford Finance LLC Quaker BioVentures

Theseus Pharmaceuticalstheseusrx.comJun 2018

BiotechCambridge, US

William C. Shakespeare(Director)in

Board Iain Dukes(Executive Officer, Director)in Carl Gordon(Director)in

Board seat Michael Rome· per SEC Form D

Co-investorsLongitude Capital Nextech Invest NexTech Ventures OrbiMed Pontifax Venture Capital Rock Springs Capital +1 more

Abcuroabcuro.comAug 2026

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBain Capital Life Sciences New Enterprise Associates (NEA)RA Capital Samsara BioCapital Sanofi Ventures Mass General Brigham Ventures +8 more

Acceleronacceleronpharma.com in 𝕏Dec 2011

A pharmaceutical company that develops medicines and vaccines for patients globally.

BiotechHealthtechMedical DevicesCambridge, US

WYLIE W. VALE(Director)JOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)inKEVIN F. MCLAUGHLIN(Executive Officer)inMATTHEW L. SHERMAN(Executive Officer)

Co-investorsBessemer Venture Partners Lightstone Ventures Lowercarbon Capital Sofinnova Ventures Venrock Collaborative Fund

Aeriepharmaaeriepharma.com inSep 2014

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.

BiotechHealthtechMedical DevicesBedminster, US

CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in

Co-investorsAlta Partners Avoro Capital Advisors OUP (Osage University Partners)Sofinnova Ventures

Affinivaxaffinivax.com in 𝕏

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.

BiotechMedical DevicesCambridge, US

Richard Malley(Director)inKamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)in

BoardRobert More(Director)Frances Heller(Director)George Siber(Director)

Co-investorsBain Capital Life Sciences EcoR1 Capital Bain Capital Rock Springs Capital T. Rowe Price

Akeroakerotx.com in 𝕏

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsAtlas Venture Frazier Life Sciences Scion Life Sciences The Innovation Space venBio Partners Versant Ventures

Apollo Health Venturesapollo.vc in 𝕏Jan 2026

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

BiotechDeep TechHealthtechLongevity

Nils Regge(Co-Founder & General Partner)in

Co-investorsBLN Capital CoastCap FJ Labs KfW Capital TruVenturo GmbH CTI Life Sciences Fund L.P.+3 more

Arcus Biosciencesarcusbio.com in 𝕏

Arcus Biosciences develops combination cancer therapies, producing small molecules and antibodies designed to be combined and advanced from Phase 1 studies through commercialization.

Biotech

Juan Jaen(Founder)in

Co-investorsAisling Capital Decheng Capital Droia Ventures EcoR1 Capital SLVC Sofinnova Ventures +2 more

Ardelyxardelyx.com 𝕏

Ardelyx is a biopharmaceutical company that develops first-in-class medicines for patients with unmet medical needs.

BiotechFremont, US

Mark Kaufmann(Executive Officer)Elizabeth Grammer(Executive Officer)inDavid Rosenbaum(Executive Officer)inJeremy Caldwell(Executive Officer)Mike Raab(Executive Officer, Director)in

BoardDavid Mott(Director)

Co-investorsHEALTHCARE ROYALTY PARTNERS New Enterprise Associates (NEA)

Arriventarrivent.com inDec 2022

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.

BiotechHealthtechMedical DevicesNewtown Square, US

Zhengbin (Bing) Yao(Executive Officer, Director)in Brent Rice(Chief Commercial Officer)in

BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)

Co-investorsCatalio Capital Management, LP General Catalyst HongShan Capital Group LAV Lilly Asia Ventures OrbiMed +2 more

Ascendis Pharmaascendispharma.com in 𝕏Nov 2014

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)inGrethe Rasmussen(Executive Officer)inHarald Rau(Executive Officer)Martin Olin(Director)Lotte S?nderbjerg(Executive Officer)Martin Auster(Executive Officer)in

Co-investorsVivo Capital Aisling Capital Avoro Capital Advisors RA Capital Sofinnova Ventures

Avenzoavenzotx.com in

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsDelos Capital INCE Capital Longwood Fund New Enterprise Associates (NEA)OrbiMed Quan Capital +3 more

Blueprint Medicinesblueprintmedicines.com in 𝕏

Blueprint Medicines is a biopharmaceutical company that discovers and develops targeted medicines for patients with diseases such as gastrointestinal stromal tumor and other conditions driven by genetic changes.

BiotechHealthtechCambridge, US

Nick Lydon(Director)Christoph S. Lengauer(Executive Officer)inChristine Bellon(Executive Officer)inKyle Kuvalanka(Executive Officer)in

BoardAlexis Borisy(Executive Officer, Director)Daniel Lynch(Director)

Co-investorsF-Prime Capital Nextech Invest RA Capital

Candid Therapeuticscandidrx.com inAug 2024

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsOrbiMed Samsara BioCapital TCG Crossover Third Rock Ventures venBio Partners Vida Ventures

Careguidecareguide.com in 𝕏Seed · Oct 2014 · $2M

CareGuide operates online marketplaces that connect people seeking care services with qualified caregivers across various verticals including pet care, home services, and childcare.

ConsumerDigital HealthHealthtechHR TechMarketplacesSaaSToronto, US

John Green in Ali Dinani(Chief Executive Officer)in Ken Scott(Chief Financial Officer)inEmir Hasanbegovic(Chief Technology Officer)in

BoardJesse Rasch

Co-investors500 Global Garage Capital Inovia Capital Structure Capital Plaza Ventures

Centessa Pharmaceuticalscentessa.com

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsAdvent Life Sciences EcoR1 Capital Medicxi Oberland Capital Scion Life Sciences Vida Ventures +1 more

Chimagen Bioscienceschimagen.com in

Chimagen Biosciences is a Shanghai-based clinical-stage biotech developing multi-specific antibody therapeutics, including T-cell and NK-cell engagers, for cancer and autoimmune diseases.

Color Healthcolor.com in 𝕏

Color Health operates a nationwide virtual cancer clinic delivering oncologist-led care, screening, and treatment management for employer, union, health plan, and public sector populations.

AI & Machine LearningDigital HealthHealthtechSan Francisco, US

Othman Laraki(CEO)in

Co-investors8VC Comcast Ventures CRV (Charles River Ventures)Dria Ventures Homebrew Kindred Ventures +9 more

ConnectiveRxconnectiverx.com in

ConnectiveRx provides hub services, patient support, and patient affordability programs that help pharmaceutical manufacturers, healthcare providers, and patients access and stay on prescribed therapies.

Digital HealthHealthtechSaaS

Co-investorsGenstar Blackstone Genstar Capital

Corvuspharmacorvuspharma.com inSep 2015

Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.

BiotechHealthtechBurlingame, US

Richard A. Miller(President & CEO, Co-Founder)inLeiv Lea(Executive Officer)in

BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Co-Founder)inTerry G. Gould(Director)

Co-investorsAvoro Capital Advisors OrbiMed

Crossoverhealthcrossoverhealth.com in 𝕏

Crossover Health operates an integrated primary care delivery model centered on member experience, using proprietary technology and care structures to expand healthcare access and accountability.

Digital HealthHealthtech

Ryan Smith

Co-investorsNorwest Venture Partners

Cue Healthcuehealth.com

Clint Sever(Founder)in

Co-investorsACME Capital Darwin Capital Decheng Capital Dentsu Ventures Prime Partners CAVU Consumer Partners+1 more

Cymabaycymabay.com in 𝕏Aug 2015

Gilead Sciences is a biopharmaceutical company headquartered in Foster City, California that discovers, develops, and delivers medicines across virology, oncology, and inflammation.

BiotechHealthtechMedical DevicesNewark, US

Harold Van Wart, Ph. D.(Executive Officer, Director)Pol Boudes(Executive Officer)Charles A. McWherter, Ph. D.(Executive Officer)Sujal Shah(Executive Officer)

BoardCarl Goldfischer, M.D.(Director)Kurt von Emster(Director)in

Co-investorsAvoro Capital Advisors Bay City Capital VantagePoint Capital Partners Abingworth

Delfi Diagnosticsdelfidiagnostics.com in

DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US

Victor Velculescu(Founder and Board Director)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)in Susan Tousi(Chief Executive Officer)in

Co-investorsAV8 Ventures Illumina Ventures Initiate Venture Partners Menlo Ventures Open Field Capital OrbiMed +5 more

Dermiradermira.com

HealthtechMenlo Park, US

Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)

Board Fred Craves(Director)in

Co-investorsAisling Capital Bay City Capital Canaan Partners New Enterprise Associates (NEA)Fidelity Investments Qiming Healthcare +1 more

Dnanexusdnanexus.com in 𝕏Apr 2015

DNAnexus operates a cloud platform for managing, analyzing, and collaborating on multiomic and clinical data, supporting bioinformatics workflows, AI/ML analytics, and cohort analysis.

AI & Machine LearningBiotechCloud ComputingData & InfrastructureMountain View, US

Andreas Sundquist(Executive Officer, Director)in Richard Daly(Executive Officer, Director)inGeorge Asimenos, PhD(Chief Product Officer)in

BoardMichael Goldberg(Director)Geoff Duyk(Director)Krishna Yeshwant(Director)in

Co-investorsClaremont Creek Ventures GV (Google Ventures)K9 Ventures Uncork Capital Wireframe Ventures

Elementelement.com in

Element Materials Technology provides materials testing, product qualification, and assurance services for customers in aerospace, space, defense, and energy sectors.

Advanced ManufacturingDeep TechDefense TechEnterprise SoftwareMedical DevicesNew Materials

Rick Sluiters(CEO of Element Aero, Space & Defense)

Co-investors3i Group Metaplanet Protocol Labs T. Rowe Price Venrock

Elementelement.market 𝕏

Element is an NFT marketplace on Ethereum where users can create, swap, and trade NFT collections, with real-time floor price and volume data tracking.

Crypto & Web3Marketplaces

Co-investorsBitDAO Mantle Network Metaplanet Protocol Labs T. Rowe Price Venrock

Element Bioscienceselementbiosciences.com in 𝕏

Element Biosciences develops biological analysis platforms and DNA sequencing tools for scientists and research institutions.

BiotechDeep TechHardwareMedical Devices

Co-investorsDraper Associates Fusion RA Capital TSVC Venrock

Everly Healtheverlywell.com in 𝕏Dec 2020 · $175M

Everlywell offers at-home lab testing kits and virtual healthcare services across multiple wellness categories including daily health screening, digestive analysis, sexual health testing, and hormone monitoring.

ConsumerDigital HealthHealthtechWellness & Fitness

Julia Cheek(Founder & CEO)in

Co-investorsAnsa Capital Breyer Capital Cerity Partners Ventures Halogen Ventures Management Company Llc Lux Capital Next Coast Ventures +10 more

Fabric Genomicsfabricgenomics.com in 𝕏

Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesOakland, US

Martin Reese(Co-Founder, President, and CEO)inMartin Reese, Ph.D.(Co-Founder, President, and CEO)Erwin Frise(Vice President of Technology and Data Science)in

Co-investorsArtis Ventures Mighty Capital Casdin Capital

Folxfolxhealth.com in 𝕏Oct 2022 · $30M

FOLX is a digital healthcare platform designed for LGBTQIA+ adults, providing inclusive and affirming medical care.

Digital HealthHealthtechBoston, US

A.G. Breitenstein(Founder)in Lena Ballantine(Executive Officer)inLiana M Guzman Weis(Executive Officer, Director)

Board Lynne Chou O'Keefe(Director)inMorgan Cheatham(Director)in Lee Shapiro(Director)in

Co-investors7wire Ventures Bessemer Venture Partners Corewell Health Ventures Define Ventures Habitat Partners Seae Ventures +2 more

Foresight Diagnosticsforesight-dx.com in 𝕏acquired by Natera · Dec 2025 · $424.5M

Foresight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types.

BiotechDigital HealthHealthtechBoulder, US

Co-investorsAgent Capital Boulder Ventures Civilization Ventures Management, Llc CU Healthcare Innovation Fund

Generation Biogenerationbio.com

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)

Board Jason Rhodes(Director)in Catherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsAtlas Venture F-Prime Capital Invus

Genomics Plcgenomics.com in 𝕏

Genomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers.

AI & Machine LearningBiotechDigital HealthHealthtechOxford, GB

Peter Donnellyin

Co-investorsF-Prime Capital

Healthcare North America Growth Stageaetion.com in

Data & InfrastructureDigital HealthHealthtechNew York, US

Sebastian G. Schneeweiss(Director)William Geary(Director)inJeremy Rassen(Executive Officer, Director)

Co-investorsB Capital Group B4 Capital Blue Lion Global Flare Capital Partners LG Technology Ventures McKesson Ventures+6 more

Hims & Hershims.com

US direct-to-consumer telehealth company selling prescription and OTC treatments online by subscription; NYSE-listed as HIMS.

Jack Abraham(Co-founder)in

Co-investors7GC & Co 8VC A-Rod Corp Atomic Brentwood Associates CAVU Consumer Partners +17 more

identifeye HEALTHidentifeye.health in

Identifeye provides a fundus imaging platform combining a portable camera device and cloud-based portal software for retinal screening in point-of-care settings.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Inscriptainscripta.com

BiotechBoulder, US

Michael Graige(Executive Officer)Ron McGrath(Executive Officer)Sri Kosaraju(Executive Officer, Director)Dianna L. DeVore(Executive Officer)

Board Roger Wyse(Director)in Bryan Roberts(Director)in

Co-investorsiGlobe Partners Korys Oak HC/FT OMX Ventures Paladin Capital Group Spruce Capital Partners +3 more

Insitroinsitro.com in 𝕏Mar 2020 · $143M

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

Daphne Koller(CEO & Founder)in Duane Valz(General Counsel)inMary Rozenman(Chief Financial Officer)in

Board Robert Nelsen(Director)Vijay Pande(Director)in

Co-investorsAndreessen Horowitz ARCH Venture Partners GV (Google Ventures)HOF Capital SoftBank Vision Fund Alexandria +7 more

Ivantis Incivantisinc.comJan 2017Acquired

Ivantis was a medical device company founded in 2007 in Irvine, California, that developed the Hydrus Microstent, a minimally invasive device for treating glaucoma during cataract surgery.

Irvine, US

David Van Meter(Executive Officer, Director)

BoardTara Butler(Director)Douglas Roeder(Director)Ali Behbahani(Director)inRandy Alexander(Director)Thong Yuen Poon(Director)

Co-investorsAscension Ventures RA Capital MemorialCare Innovation Fund New Enterprise Associates (NEA)

Jade Biosciencesjadebiosciences.com in

Jade Biosciences develops therapeutic antibodies targeting autoimmune diseases, with a lead candidate in clinical development for immunoglobulin A nephropathy, a chronic kidney disease.

BiotechHealthtech

Co-investorsFrazier Life Sciences

Karyopharmkaryopharm.com in 𝕏Dec 2022

Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma.

BiotechHealthtechNewton, US

Stuart Poulton(Executive Officer)inMichael Mano(Executive Officer)in Reshma Rangwala(Executive Officer)in Richard Paulson(Executive Officer, Director)inStephen Mitchener(Executive Officer)inMichael Mason(Executive Officer)in

Co-investorsAvoro Capital Advisors HEALTHCARE ROYALTY PARTNERS RA Capital

Khartis Therapeuticskhartis.com in

Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.

BiotechMedical Devices

Co-investorsNextech Invest Alexandria Lilly Asia Ventures Longwood Fund

Kira Pharmaceuticalskirapharma.com in

Kira Pharmaceuticals is a biotech company developing therapies targeting complement biology to treat complement-mediated diseases.

BiotechHealthtechCambridge, US

Wenru Song(Founder)in

Co-investorsQuan Capital Vivo Capital Ikarian Capital

Kriyakriya.co inMay 2022 · $270M

Kriya provides working capital loans and business finance products to UK and European businesses, helping them manage cash flow, fund wholesale orders, and scale their buyer base.

FintechSaaS

Anil Stocker(Founder)in

Co-investorsMouro Capital Northzone Bluebird Ventures JDRF T1D Fund Narya Capital Patient Square Capital +2 more

Kriya Therapeuticskriyatherapeutics.com in 𝕏Jun 2021 · $1.2B

Kriya Therapeutics is a biopharmaceutical company that develops and manufactures one-time gene therapies aimed at treating prevalent chronic diseases.

BiotechHealthtechMorrisville, US

Shankar Ramaswamy(Co-Founder, Chairman & CEO)in Roger Jeffs(Co-Founder & Vice Chairman)inFraser Wright(Scientific Co-Founder & Chief Gene Therapy Officer)in Shankar Ramaswamy, M.D.(Founder)in Michele Stone(Chief Scientific Officer)inKatherine Eade(Chief Legal Officer)

Co-investorsPatient Square Capital Premji Invest Amplo Ventures Bluebird Ventures JDRF T1D Fund Narya Capital +2 more

Latigo Biolatigobio.comJan 2025

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.

BiotechHealthtechMedical DevicesThousand Oaks, US

Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)

Board Beth Seidenberg(Director)in Jim Tananbaum(Director)in Deborah Palestrant(Director)inKevin Raidy(Director)

Co-investorsAccess Biotechnology Kern Capital, LLC Sanofi Ventures 5AM Ventures Westlake Village BioPartners

Lucira Healthlucirahealth.com in

Lucira Health manufactures portable diagnostic devices that connect to smartphones to test bodily fluids for infectious diseases, enabling rapid results outside of clinical settings.

BiotechHealthtechMedical DevicesEmeryville, US

Debkishore Mitra(Founder)inJohn R. Waldeisen(Director)

BoardErik T. Engelson(Executive Officer, Director)Justin Butler(Director)Tuff Yen(Director)Steve Tablak(Director)

Co-investors11.2 Capital ShangBay Capital LLC Y Combinator OS Fund

Lyelllyell.com inMar 2020

Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.

BiotechDeep TechHealthtechMedical DevicesBothell, US

Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)in Heather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)

Co-investorsARCH Venture Partners venBio Partners 8VC Axial VC

Mammoth Biosciencesmammoth.bio in 𝕏

Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.

BiotechDeep TechMedical DevicesBrisbane, US

Jennifer Doudna(Founder)in Trevor Martin(Co-founder, Chief Executive Officer)in Janice Chen(Co-founder, Chief Scientific Officer & President, Research)in Lucas Harrington(Co-founder)in Ashley Tehranchi(Executive Officer, Director)in

BoardUrshit Parikh(Director)

Co-investors8VC Berkeley Frontier CALIFORNIA INNOVATION Decheng Capital Mayfield Fund Mission Bay Capital +9 more

Midimidi.healthFeb 2026 · $100M

Virtual women's health clinic offering insurance-covered perimenopause, menopause and midlife care in all 50 U.S. states.

Joanna Strober(Founder)in

Co-investors25Madison Felicis Ventures Icon Ventures SteelSky Ventures Advance Venture Partners Gingerbread Capital +4 more

Mirviemirvie.com inJul 2025 · $60M

Mirvie develops an RNA-based platform for early detection of pregnancy complications, enabling proactive intervention before complications become critical.

BiotechFemTechHealthtechSouth San Francisco, US

Maneesh Jain(Executive Officer, Director, Promoter)inStephen Quake(Director)

BoardLisa Iverson(Director)Ursheet Parikh(Director)in Min Cui(Director)in Samir Kaul(Director)in

Co-investorsDecheng Capital Mayfield Fund Portfolia BlackRock General Catalyst GV (Google Ventures)+1 more

Myomemyome.com in 𝕏

MyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.

BiotechDigital HealthHealthtechMedical Devices

Akash Kumar(Chief Medical and Scientific Officer / Co-Founder)inKate Im(Senior Vice President of Research / Co-Founder)in

Co-investorsHOF Capital Samsung Next

Mythic Therapeuticsmythictx.comDefunct

Mythic Therapeutics was a clinical-stage biotech developing next-generation antibody-drug conjugates for cancer using its proprietary FateControl technology.

BiotechWaltham, US

Brian Fiske(Executive Officer, Director)George Eliades(Executive Officer, Director)in Sandra Poole(Executive Officer)inAlex Nichols(Executive Officer, Director, Promoter)

Board Bryan Roberts(Director)inPeter Hecht(Director)

Co-investorsHemi Ventures, Llc Lifeforce Capital Refactor Capital Venrock Associates

Nested Therapeuticsnestedtx.com in 𝕏Oct 2022

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.

AI & Machine LearningBiotechHealthtech

Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)inDarrin Miles(Chief Executive Officer)in Philip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)in

Co-investorsVersant Ventures Sixty Degree Capital Cowen Healthcare Investments Goldman Sachs Section 32

Neurodermneuroderm.com in

Novavax, Inc. (Alumni)novavax.com

Novavax develops protein-based nanoparticle vaccines paired with its Matrix-M adjuvant to produce broad, long-lasting immune responses.

BiotechHealthtech

Nurix Therapeuticsnurixtx.com in 𝕏

Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

Arthur T. Sands(Executive Officer, Director)in Gwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)

BoardDavid Goeddel(Director)inMark Goldsmith(Director)

Co-investorsBain Capital Life Sciences EcoR1 Capital Sofinnova Ventures The Column Group

Odyssey Therapeuticsodysseytx.com in 𝕏

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)in

Board Jill Carroll(Director)in Carl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in

Co-investorsActivant Capital Balderton Capital Catalio Capital Management, LP Global BioAccess Fund GreatPoint Ventures Jeito Capital +7 more

OptiNoseoptinose.com

Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists.

BiotechHealthtechMedical DevicesYardley, US

Per Djupesland(Executive Officer, Director)inMichele Janis(Executive Officer)Peter Miller(Executive Officer, Director)inTerrence Terifay(Executive Officer)Ramy Mahmoud(Executive Officer)in

BoardKlaas De Boer(Director)

Co-investorsMVM Life Science Partners

Orchard Therapeuticsorchard-tx.com in 𝕏

Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.

BiotechDeep TechHealthtechMedical DevicesLondon, GB

Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)

Board Bobby Gaspar(Scientific Founder)in

Co-investorsAlbionVC F-Prime Capital UCL Technology Fund Agent Capital Baillie Gifford ORI Capital +1 more

Peloton Therapeuticspelotontherapeutics.comacquired by Merck · May 2019 · $2.2B

Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.

BiotechDigital HealthMedical Devices

Co-investorsCurative Ventures Nextech Invest The Column Group Vida Ventures

Pharvarispharvaris.com in 𝕏

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsBain Capital Life Sciences Kurma Partners venBio Partners

Pinnacle Medicinespinnaclemedicines.com inMar 2026

Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.

BiotechDigital HealthDoylestown, US

Chengzao Sun(Founder)inSandeep Somani(Founder)in

Co-investorsQuan Capital RA Capital LAV OrbiMed

Puma Biotechnology, Inc. (Alumni)pumabiotechnology.com

Puma Biotechnology is a biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics for cancer treatment.

BiotechHealthtech

Quantum Siquantum-si.com in 𝕏

Quantum-Si develops next-generation protein sequencing technology that enables single amino acid detection by combining biology, chemistry, artificial intelligence, and semiconductor technology.

BiotechDeep TechHardwareMedical Devices

Jeff Hawkins(CEO)inJeff Keyes(Chief Financial Officer)inChristian LaPointe(General Counsel)inTodd Rearick(Chief Technology Officer)inLindsay Thompson(Chief Human Resources Officer)in

Co-investorsHighCape Capital YuanBio Venture Capital

RAPT Therapeuticsrapt.com inacquired by GSK · Jan 2026 · $2.2B

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases.

BiotechHealthtech

Co-investorsFrazier Life Sciences Kleiner Perkins Medicxi Solasta Ventures The Column Group OrbiMed

RayTheraraythera.com

RayThera develops small molecule therapies targeting unmet needs in immunology.

BiotechHealthtech

Co-investorsOrbiMed

Redesign Healthredesignhealth.com in

Redesign Health is a venture capital and applied technology platform that builds and invests in next-generation healthcare companies using AI-native strategies.

AI & Machine LearningDigital HealthHealthtech

Co-investorsCVS Health Ventures Declaration Partners Forerunner Ventures Mantis Capital RiverPark Ventures Samsung Next

Regulus Therapeutics Inc.regulusrx.com in 𝕏acquired by Novartis · Apr 2025 · $1.7B

Regulus Therapeutics was a San Diego-based clinical-stage biopharmaceutical company developing oligonucleotide drugs that inhibit disease-causing microRNAs.

BiotechHealthtechSan Diego, US

Neil Gibson(Executive Officer)Kleanthis Xanthopoulos(Executive Officer, Director)

BoardB. Lynne Parshall(Director)Mark G. Foletta(Director)John Maraganore(Director)Douglas E. Williams(Director)

Co-investorsNew Enterprise Associates (NEA)SR One Capital Management

Rhythm Pharmaceuticalsrhythmtx.com in 𝕏Jan 2017

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)in Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in

Board Edward T. Mathers(Director)in Jonathan Silverstein(Director)in Neil Exter(Director)in

Co-investorsHEALTHCARE ROYALTY PARTNERS New Enterprise Associates (NEA)Pfizer Venture Investments OrbiMed Third Rock Ventures

Sangamo Therapeuticssangamo.com in 𝕏

Sangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy.

BiotechDeep TechHealthtechMedical DevicesUnknown based on the provided page content, US

Sandy Macrae(Chief Executive Officer)in

Co-investorsCalifornia Technology Ventures Foothill Ventures Ridgeback Capital

Signant Healthsignanthealth.com in 𝕏

Signant Health provides software platforms and clinical trial solutions for life sciences companies to manage patient-reported outcomes, evidence generation, and digital endpoints in drug development programs across multiple therapeutic areas.

BiotechDigital HealthEnterprise SoftwareHealthtechMedical DevicesSaaSBlue Bell, US

Roger Smith(Chief Executive Officer)in

Co-investorsGenstar Capital Genstar

Site by Goodlabgoodlab.media in

Good Lab is a brand and design agency serving early-stage, rapid-growth ventures in health, wellness, environmental sciences, and life sciences.

Creator EconomyMarketing Tech

John Montgomery(Founder)in

Slate Medicinesslatemedicines.com inFeb 2026

Slate Medicines is a clinical-stage biotechnology company.

BiotechMedical DevicesBoston, US

Sara Pacheco(Executive Officer)Neil Buckley(Executive Officer, Director)inGregory Oakes(Chief Executive Officer and Board Director)in

BoardTim Lohoff(Director)Cindy Xiong(Director)in Andrew Levin(Director)

Co-investorsRA Capital

SomaLogicsomalogic.comNov 2020 · $121M

SomaLogic develops proteomics tools that help researchers measure protein function and study human biology across a range of scientific applications.

BiotechDeep TechHealthtechBoulder, US

Larry Gold(Director)inLarry Gold PhD(Founder)inDaniel Muehl(Executive Officer)Byron Hewett(Executive Officer, Director)in

BoardCharles Lillis(Director)Youichi Yabuuchi(Director)

Co-investorsKhosla Ventures Casdin Capital Magnetar Capital Reimagined Ventures Soleus Capital T. Rowe Price

Stepfulstepful.com in 𝕏

Stepful provides affordable, online healthcare education programs with live instruction and personalized coaching to train students for healthcare careers.

EdTechHealthtechNew York City, US

Carl Madi(CEO and Co-Founder)in Tressia Hobeika(Founder)inEdoardo Serra(Founder)in

Co-investorsAlleyCorp Equal Opportunity Ventures Oak HC/FT SemperVirens Venture Capital Unpopular Ventures Y Combinator +2 more

Structure Therapeuticsstructuretx.com in 𝕏

Co-investorsF-Prime Capital Qiming Venture Partners

Tassotassoinc.com in 𝕏Dec 2019

Tasso develops diagnostic testing devices and platforms for home use, enabling patients to perform health monitoring and inform clinical decisions outside traditional healthcare settings.

Digital HealthHealthtechMedical DevicesSeattle, US

Ben Casavant(Co-Founder and Chief Executive Officer)in Erwin Berthier(Co-Founder and Chief Technology Officer)inAlan Levy(Director)

BoardElizabeth Hambrecht(Director)Paul Conley(Director)in

Co-investorsJ2 Ventures OMX Ventures RA Capital Techstars Venture Capital Investment Management Vertical Venture Partners

Theseustheseus.us inApr 2021

Theseus builds robotic situational awareness software using visual positioning for drones that operate in GPS-denied environments.

Advanced ManufacturingAI & Machine LearningDefense TechHardwareRoboticsSan Francisco, US

Ian Laffey(Founder)in Sacha Lévy(Founder)in

Co-investorsY Combinator Antler First Round Capital Longitude Capital Lux Capital NexTech Ventures +4 more

Third Arc Biothirdarcbio.com inJul 2024

Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.

BiotechMedical DevicesLower Gwynedd, US

Joseph Erhardt(Executive Officer)inPeter Lebowitz(Executive Officer, Director)

Board Arjun Goyal(Director)inOtello Stampacchia(Director)in Francesco Draetta(Director)in

Co-investorsAndreessen Horowitz Vida Ventures abrdn plc Biotechnology Value Fund Hillhouse Investment Omega Funds +1 more

Thymemeetthyme.com inNov 2025 · $97MAcquired

Thyme has partnered with Altruist to create Hazel, an AI product for wealth management professionals.

AI & Machine LearningEnterprise SoftwareFintechSan Francisco, US

Daniel Lantz(Founder)in Fernando San Martin(Founder)in

Co-investorsY Combinator AlleyCorp Concord Health Partners CVS Health Ventures Frist Cressey Ventures Humana +1 more

Thyme Carethymecare.com in 𝕏Sep 2025

Thyme Care develops software to enhance care coordination and outcomes for cancer patients.

Digital HealthHealthtechNashville, US

Robin Shah(Executive Officer, Director)in Bobby Green(Founder)in

Board Brian Belsky(Director)in Elizabeth Canis(Director)in Brenton Fargnoli(Director)in Vineeta Agarwala(Director)in

Co-investorsAlleyCorp Andreessen Horowitz Corewell Health Ventures CVS Health Ventures Echo Health Ventures Frist Cressey Ventures +5 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Allergen Research Fl2021-001 Interline Therapeutics, Inc.Spear Bio89 Bio, Inc. (Alumni)Abdera TherapeuticsAcceleron PharmaAduro BiotechAerie Pharmaceuticals, Inc. (Alumni)Aimmune TherapeuticsAmbit Biosciences CorporationAudentesAvanir PharmaceuticalsAveXis Bellicum PharmaceuticalsBiodelivery Sciences International CopyBiohaven PharmaceuticalCopyDetect, Inc.Dyax CorpEidos TherapeuticsEngene Holdings IncEpizyme, Inc. (Alumni)EvonetixFibrogenGalileoIkena Oncology, Inc.ImageneBio, Inc. (Alumni)Immpact Bio UsaImmunomedics, Inc. (Alumni)IndomoIntarcia TherapeuticsKinnate Biopharma (Alumni)Lundbeck Seattle Biopharmaceuticals IncModal Therapeutics Inc.Momenta Pharmaceuticals, Inc. (Alumni)MyokardiaNanostringNgm BiopharmaceuticalsObsidian Therapeutics, Inc.Phaxiam Therapeutics S APopulation Health Investment CoPropeller Bio, LLCSestina BioSollis HealthSotera WirelessTenSixteen BioTessera TherapeuticsThe Medicines CompanyTP Therapeutics

Browse all 212 investments with full details →

▶12 more tracked companies

Turning Point TherapeuticsUniqureVeliaVenatorx PharmaceuticalsVerona Pharma Verve Therapeutics Vignette BioVitae PharmaceuticalsVoyager Therapeutics (Alumni)Xaira TherapeuticsXintheraZenefits

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 88

59 IPOs · 29 acquisitions · showing 79

AlumisNASDAQ: ALMSFulcrum TherapeuticsNASDAQ: FULC10x Genomics 1-colorNASDAQ: TXGAclaris TherapeuticsNASDAQ: ACRSAdagio TherapeuticsNASDAQ: IVVDAdaptimmuneOTC: ADAPYAdaptive BiotechnologiesNASDAQ: ADPTAdicet BioNASDAQ: ACETAlectorNASDAQ: ALECAllogene TherapeuticsNASDAQ: ALLOAlx OncologyNASDAQ: ALXOArbutus Biopharma CorporationNASDAQ: ABUSAura BiosciencesNASDAQ: AURABeam TherapeuticsNASDAQ: BEAMBicara TherapeuticsNASDAQ: BCAXCasi PharmaceuticalsOTC: CASIFCelldex Therapeutics, Inc.NASDAQ: CLDXCG OncologyNASDAQ: CGONCompass TherapeuticsNASDAQ: CMPXCrineticsNASDAQ: CRNXCullinan TherapeuticsNASDAQ: CGEMCytokineticsNASDAQ: CYTKDenali TherapeuticsNASDAQ: DNLIDisc MedicineNASDAQ: IRONEdgewise TherapeuticsNASDAQ: EWTXGH ResearchNASDAQ: GHRSGRAILNASDAQ: GRALHinge HealthNYSE: HNGEInsmedNASDAQ: INSMIntellia TherapeuticsNASDAQ: NTLAInvivydNASDAQ: IVVDKerostxNASDAQ: KROSKura OncologyNASDAQ: KURAMadrigalNASDAQ: MDGLMaze TherapeuticsNASDAQ: MAZENateraNASDAQ: NTRAOlemaNASDAQ: OLMAOmeros Corp.NASDAQ: OMERParabilis MedicinesNASDAQ: PBLSQuince TherapeuticsNASDAQ: QNCXRelayNASDAQ: RLAYReplimuneNASDAQ: REPLRevolution MedicinesNASDAQ: RVMDRxsightNASDAQ: RXSTScynexisNASDAQ: SCYXSeaport TherapeuticsNASDAQ: SPTXSilence TherapeuticsNASDAQ: SLNSolid BiosciencesNASDAQ: SLDBSutroVaxNASDAQ: PCVXSyndax PharmaceuticalsNASDAQ: SNDXTango TherapeuticsNASDAQ: TNGXVaxcyteNASDAQ: PCVXVerastemNASDAQ: VSTMWave Life SciencesNASDAQ: WVEXenon PharmaNASDAQ: XENE89 Bio, Inc. (Alumni)acq. by RocheAduro Biotechacq. by Chinook TherapeuticsAimmune Therapeuticsacq. by Nestlé Health ScienceAmbit Biosciences Corporationacq. by Daiichi SankyoAudentesacq. by Astellas PharmaAvanir Pharmaceuticalsacq. by Otsuka Pharmaceutical Co., Ltd.Bellicum Pharmaceuticalsacq. by The University of Texas MD Anderson Cancer CenterBiohaven Pharmaceuticalacq. by PfizerDyax Corpacq. by ShireEidos Therapeuticsacq. by BridgeBio PharmaEpizyme, Inc. (Alumni)acq. by Ipsen SAForesight Diagnosticsacq. by NateraImmpact Bio Usaacq. by Lyell Immunopharma, Inc.Immunomedics, Inc. (Alumni)acq. by Gilead SciencesMomenta Pharmaceuticals, Inc. (Alumni)acq. by Johnson & JohnsonMyokardiaacq. by Bristol Myers SquibbNanostringacq. by BrukerNgm Biopharmaceuticalsacq. by The Column GroupPeloton Therapeuticsacq. by MerckRAPT Therapeuticsacq. by GSKRegulus Therapeutics Inc.acq. by NovartisSestina Bioacq. by InscriptaSotera Wirelessacq. by Foxconn (Hon Hai Precision Industry)The Medicines Companyacq. by Novartis

Portfolio news

latest coverage across their companies

Silence Therapeutics at Morgan Stanley conference: divesiran drives focus By Investing.com

Silence Therapeutics · investing.com · Sep 16, 2026

El director ejecutivo de Rhythm Pharmaceuticals vende acciones por 5,13 millones de dólares Por Investing.com

Rhythm Pharmaceuticals · es.investing.com · Sep 15, 2026

GSK Stock Rises After Berenberg Upgrade and $750M Chimagen Deal - CoinCentral

Chimagen Biosciences · coincentral.com · Sep 15, 2026

Stifel cuts Olema Pharmaceuticals price target on trial concerns By Investing.com

Olema · investing.com · Sep 14, 2026

Your Weekly Biotech News Fix | Ep. 1078 - BowTiedBiotech

Karyopharm · bowtiedbiotech.substack.com · Sep 12, 2026

Goldman Sachs reinstates Element Solutions stock rating at Buy on merger termination By Investing.com

Element · investing.com · Sep 11, 2026

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?

Madrigal · finance.yahoo.com · Sep 10, 2026

Vaxcyte at Cantor conference: broad vaccine bet nears key test By Investing.com

Vaxcyte · uk.investing.com · Sep 9, 2026

IPO stake values · per SEC filings · 8

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
10x Genomics 1-color	9.6%	$110.00	Sep 2020	$804.4M
Alumis	24.4%	$16.00	Jun 2024	$202.4M
Kerostx	6.3%	$50.00	Nov 2020	$71.4M
Cullinan Therapeutics	6.0%	$21.00	Jan 2021	$53M
Maze Therapeutics	5.3%	$16.00	Jan 2025	$37.3M
Replimune	6.5%	$15.00	Jul 2018	$30.1M
Wave Life Sciences	6.4%	$16.00	Nov 2015	$21.3M
Scynexis	5.0%	$7.70	Apr 2015	$5.1M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has Foresite Capital made?: Foresite Capital has 212 tracked investments, 88 of which have exited, including 11 dated in the last 24 months.
What stage does Foresite Capital invest at?: Foresite Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does Foresite Capital focus on?: Foresite Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is Foresite Capital located?: Foresite Capital is headquartered in West Hollywood, US.
Does Foresite Capital lead rounds?: Foresite Capital has led 7 of the 31 rounds where its role is on record.
Who does Foresite Capital co-invest with?: Foresite Capital most often shares deals with RA Capital, OrbiMed, ARCH Venture Partners, among 247 tracked co-investors.

From the blog

visit blog ↗

Foresite Capital has invested in healthcare innovations across diagnostics, urgent care delivery, and neuropsychiatric drug development, with a focus on companies addressing significant unmet patient needs through differentiated technologies and consumer-driven models. AI summary

Q&A with Foresight Diagnostics on their acquisition by NateraDec 2025Foresite Capital portfolio company Foresight Diagnostics was acquired by Natera; founders discuss leadership lessons from building and exiting the ctDNA diagnostics company.Sollis Health: Redefining Urgent and Emergency CareApr 2025Foresite led a $35M Series B in Sollis Health, a membership-based urgent and emergency care provider with 24/7 access and strong unit economics.Welcoming Seaport Therapeutics to Our PortfolioOct 2024Foresite invested in Seaport Therapeutics, a neuropsychiatric drug developer using a novel lymphatic-delivery platform for major depressive disorder treatments.

Media · Podcasts & interviews

featuring the team

Jim Tananbaum, Foresite Capital Founder on Healthcare & Life Sciences

Grace Gong · Jim Tananbaum

How AI Is Rewriting Drug Discovery and Biotech Investing | Jim Tananbaum of Foresite Capital

Nicholas Moran · Jim Tananbaum

Why Jim Tananbaum, Founder & CEO of Foresite Capital, is excited by the Element AVITI

Element Biosciences · Jim Tananbaum

Images

Co-investors · 29

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

$1M – $75M

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 15

Aclaris Therapeutics Adaptimmune Beam Therapeutics Bicara Therapeutics Compass Therapeutics Denali Therapeutics Insmed Blueprint Medicines Engrail Therapeutics Generation Bio Genomics Plc Orchard Therapeutics Verve Therapeutics Xaira TherapeuticsStructure Therapeutics

$3M – $10M

venBio Partners

venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.

Both backed · 14

Alumis Alx Oncology Aura Biosciences Compass Therapeutics Parabilis Medicines Syndax Pharmaceuticals Akero Candid Therapeutics Lyell Pharvaris TP Therapeutics Verona Pharma Verve TherapeuticsAbdera Therapeutics

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 13

Adaptimmune Xenon Pharma Abcuro Ardelyx Avenzo Curisium Dermira Ivantis Inc Regulus Therapeutics Inc.Rhythm Pharmaceuticals Verona Pharma Xaira TherapeuticsHealthcare North America Growth Stage

$200K – $40M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 13

Beam Therapeutics Denali Therapeutics GRAIL Kura Oncology Maze Therapeutics Parabilis Medicines Seaport Therapeutics Bit Bio Insitro Lyell Remix Therapeutics Verve Therapeutics Xaira Therapeutics

$50K – $250M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 12

Adagio Therapeutics Beam Therapeutics Denali Therapeutics Invivyd Maze Therapeutics Parabilis Medicines Cerevance Dnanexus Insitro Midi Mirvie Verve Therapeutics

$250K – $50M

Venrock

Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.

Both backed · 7

10x Genomics 1-color Acceleron Element Element Biosciences Inscripta ZenefitsVitae Pharmaceuticals

$500K – $10M

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 7

Disc Medicine Intellia TherapeuticsReplimuneAkero Generation Bio Ikena Oncology, Inc.Remix Therapeutics

$500K – $1M

The Column Group

The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.

Both backed · 7

Revolution Medicines Arcus Biosciences Ngm Biopharmaceuticals Nurix Therapeutics Peloton Therapeutics RAPT Therapeutics Remix Therapeutics

$30M

Aisling Capital

Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.

Both backed · 7

Aclaris Therapeutics Bicara Therapeutics Arcus Biosciences Ascendis Pharma Dermira Eidos Therapeutics Verona Pharma

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

Both backed · 5

Maze Therapeutics Insitro Third Arc Bio Thyme Care Zenefits

$500K – $50M

▶17 more co-investors

Pontifax Venture Capital 5AM Ventures Deerfield Management Company Menlo Ventures Flare Capital Partners Westlake Village BioPartners First Round Capital Torch Capital Civilization Ventures Management, Llc Sequoia Capital Bain Capital Ventures General Atlantic Wildcat Venture Partners Molten Ventures Northpond Ventures Maverick Capital Recode Ventures

Firms observed investing alongside Foresite Capital, from public investor directories. Shared companies are the overlap with Foresite Capital's recorded portfolio.

Similar investors

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Basecamp Fund

A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.

$100K – $10M

Alumni Ventures

Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.

NJF Capital is the venture investment arm of NJF Holdings, the private investment group founded by Nicole Junkermann. It backs transformative entrepreneurs building industry-defining technologies with global scale potential.

Featured in lists

Investors & VC Firms in North America Investors & VC Firms in United States Seed Investors & VC Firms Series A Investors & VC Firms Pre-Seed Investors & VC Firms Seed Investors & VC Firms in North America Seed Investors & VC Firms in United States Growth Investors & VC Firms Series A Investors & VC Firms in North America Series B Investors & VC Firms Series A Investors & VC Firms in United States AI & Machine Learning Investors & VC Firms

Website & social

foresitecapital.com

/foresite-capital-management @foresitecapital

signal ↗crunchbase ↗Blog ↗

As published on the firm's website.

Contact

West Hollywood9200 Sunset Boulevard
Suite PH1
West Hollywood, CA 90069
United States

New York1330 Avenue of the Americas
35th Floor
New York, NY 10019
United States

Phone310 981 3630

FoxScore

Combines investment activity, responsiveness, founder feedback, closing rate and follow-through reported by founders on Fox. Sign up to see it.

Your history

Foresite Capital isn't in your CRM yet.

+ Add to CRM

Track outreach, deck opens, and next steps across your whole raise.

✨ Smart outreach

✨ Best warm path

Funds

FORESITE CAPITAL FUND VI LPvintage 2022 · 494 LPs · 506(b)$1.1BAUM

FORESITE CAPITAL VI-A, LLCvintage 2021 · 18 LPs · 506(b)$18MAUM

FORESITE CAPITAL FUND V, L.P.vintage 2019 · 406 LPs · 506(b)$753.9MAUM

FORESITE CAPITAL OPPORTUNITY FUND V, L.P.vintage 2019 · 406 LPs · 506(b)$227.4MAUM

FORESITE CAPITAL FUND IV, LPJul 2026 · 178 LPs$860MAUM

FORESITE LABS FUND I, L.P.Jul 2026 · 97 LPs$130.8MAUM

FORESITE CAPITAL FUND III, LPJul 2026 · 163 LPs$110.7MAUM

FORESITE CAPITAL FUND II, LPJul 2026 · 139 LPs$10.8MAUM

FORESITE PUBLIC & CROSSOVER OPPORTUNITIES FUND I, L.P.Jul 2026

also operates 1 feeder

Source: SEC Form ADV Schedule D and EDGAR Form D filings. AUM is gross asset value as reported by the adviser.

Latest on 𝕏

Foresite Capital @foresitecapital

Today we announced Fund VI, which represents hard work from many members of our team. So grateful to our investors for their support. Read more in @FierceBiotech: @https://www.fiercebiotech.com/biotech/foresite-raises-900m-make-big-bets-one-best-biotech-investment-environments

Jun 12, 2024 · ♥ 7 · ⇄ 2

Foresite Capital @foresitecapital

Today we welcome @xaira_therapeutics to our portfolio, emerging from stealth with $1B in committed capital; jointly incubated by Arch Venture Partners / @rtnarch and @ForesiteLabs and led by Marc Tessier-Lavigne. Read more: https://t.co/Ge0Kfn0jS7

Apr 23, 2024 · ♥ 8 · ⇄ 2

Foresite Capital @foresitecapital

We welcome Hadi Tabbaa, our new managing director of investor relations and business development! With 2+ decades of experience, Hadi is set to strengthen our investor partnerships and bring invaluable expertise to Foresite Capital. Welcome aboard, Hadi! https://t.co/dDmXFx8lPf https://t.co/BHYXeHBvsP

Sep 28, 2023 · ♥ 4 · ⇄ 1